Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
OpenAI Restricts Astra AI Over Cyberattack Risks 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
BURLINGTON, Mass., March 01, 2018 -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer and Troy Ignelzi, chief financial officer of scPharmaceuticals, will present at the Cowen 38th Annual Health Care Conference at 10:40 a.m. ET on Wednesday, March 14, 2018, at the Boston Marriott Copley Plaza in Boston, MA.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.scpharmaceuticals.com for ninety days.
About scPharmaceuticals
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (IV) delivery.
Contacts:
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
[email protected]
Christopher F. Brinzey
Westwicke Partners, 339-970-2843
[email protected]
